Bioresorbable Scaffolds: Clinical Outcomes and Considerations
1Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, via Citelli 6, Catania 95124, Italy.
Interventional Cardiology Clinics
|June 6, 2017
Summary
Bioresorbable scaffolds (BRS) offer potential advantages over metallic drug-eluting stents (DESs) by aiming to reduce late coronary events. Current research reviews Absorb BRS outcomes and other emerging competitors in the field.
Area of Science:
- Cardiovascular medicine
- Biomaterials science
- Medical device engineering
Background:
- Metallic drug-eluting stents (DESs) are associated with late coronary events.
- Bioresorbable scaffolds (BRS) are engineered to overcome this limitation.
- BRSs aim for comparable safety and efficacy to DESs before complete bioresorption.
Purpose of the Study:
- To review contemporary clinical outcomes of the Absorb BRS.
- To provide an updated overview of competing BRS technologies.
- To assess the current state of BRS development in interventional cardiology.
Main Methods:
- Review of randomized clinical studies on the Absorb BRS.
- Analysis of clinical data from various BRS manufacturers.
- Synthesis of current evidence on BRS safety and efficacy.
Main Results:
- Clinical outcomes of the Absorb BRS have been documented in several randomized trials.
- Multiple manufacturers are advancing their BRS technologies.
- The field of BRS is rapidly evolving with new clinical data emerging.
Conclusions:
- BRSs hold promise for reducing late coronary events compared to DESs.
- Ongoing research and development are crucial for BRS technology advancement.
- Further clinical validation is necessary to establish BRS as a standard of care.
